A Novel Human Factors Approach for a New Platform-Based, Breath-Triggered Nebuliser
A Novel Human Factors Approach for a New Platform-Based, Breath-Triggered Nebuliser
Explore the latest news and publications, innovation milestones, and drug-device insights from PARI and our pharmaceutical partners leveraging eFlow® Technology.
A Novel Human Factors Approach for a New Platform-Based, Breath-Triggered Nebuliser
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease
A Novel HF User Characteristics Assessment Approach for a New Platform-Based, Breath-Triggered Nebulizer in Inhalation Therapy
From Continuity to Competitive Edge – How Long-Term Collaboration Drives HF Program Success
